Ozempic vs Wegovy
Same molecule, two labels, two price tags.
| Attribute | Ozempic | Wegovy |
|---|---|---|
| Molecule | Semaglutide | Semaglutide |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Frequency | Once weekly injection | Once weekly injection |
| Format | Prefilled pen, injector-dialed dose | Prefilled single-dose pen |
| Monthly price (CAD) | $250–310/mo retail ($252 at Costco) | $400–570/mo, $540–570 at maintenance dose |
| Approval / indication in Canada | Type 2 diabetes management | Chronic weight management |
| Availability | Widely stocked, most pharmacies | Widely stocked, most pharmacies |
One drug, two brand names
Ozempic and Wegovy are both built on semaglutide, the same active molecule made by Novo Nordisk. What separates them on paper is not chemistry but paperwork: Health Canada approved Ozempic for managing type 2 diabetes, and approved Wegovy, at a higher maintenance dose, for chronic weight management. Both are once-weekly injections delivered through a prefilled pen, and both work by mimicking a gut hormone that slows digestion and reduces appetite.
The practical difference patients notice is dose. Wegovy's labelled maintenance strength is higher than the highest dose typically used for Ozempic, which is part of why Wegovy tends to carry a larger average weight-loss effect in trial data and why it costs more per month at pharmacy. Ozempic can be, and often is, prescribed off-label for weight management at doses that overlap with what's used for diabetes — a common and legal practice, though it is a different regulatory pathway than a Wegovy prescription.
Why the price gap exists
Wegovy's higher list price reflects both the higher milligram dose in its maintenance pens and its indication-specific manufacturing and packaging. Ozempic, priced against a diabetes formulary in most provinces, benefits from broader public and private drug-plan coverage since diabetes management is a covered condition virtually everywhere in Canada. Wegovy, filed as a weight-management drug, falls into a different reimbursement category — no provincial public plan currently covers a GLP-1 for weight loss alone, and only about three in ten employer private plans extend coverage to that indication.
That coverage gap is often the real driver of which drug a patient ends up on, independent of which one might work better for them. Someone with type 2 diabetes and overweight or obesity may be prescribed Ozempic first simply because their diabetes diagnosis makes it a covered, on-label option, while a metabolically healthy patient seeking weight loss alone has no such shortcut into Ozempic and faces the full, uncovered cost of Wegovy.
What generic entry means for this pair
Novo Nordisk's Canadian data exclusivity on semaglutide expired in January 2026, and the company has since launched its own authorized generics — Plosbrio, mirroring Ozempic, and Poviztra, mirroring Wegovy — alongside third-party generics entering the market. As more manufacturers file competing versions of both the diabetes and weight-management formulations, expect list prices on both sides of this comparison to keep drifting downward through 2026, though the diabetes-labelled product will likely stay the cheaper of the two given its broader coverage base.
The verdict: questions to ask your doctor
The starting question for a doctor isn't which brand name to ask for — it's which indication actually applies. If diabetes management is the primary goal, that conversation naturally points toward the diabetes-labelled product and the coverage that comes with it. If weight management on its own is the goal, ask directly what code your insurer will use to adjudicate the claim, because that single administrative detail can change your monthly cost by hundreds of dollars regardless of which pen ends up in your fridge.
It's also worth asking your prescriber how off-label dosing compares to an on-label Wegovy prescription in your specific case — the dose ranges overlap, and the clinical reasoning for choosing one path over the other is something only your doctor can weigh against your health history.
Finally, ask your pharmacist or benefits administrator whether a manufacturer savings program or a newly available generic changes the math before you commit to a specific product. With multiple semaglutide versions now on the Canadian market, the cheapest path to the same active ingredient shifts often enough that it's worth checking at each renewal rather than assuming last month's price still holds.
Frequently asked
- Is Wegovy just a higher dose of Ozempic?
- They share the same active ingredient, semaglutide, but Wegovy is approved and dosed specifically for chronic weight management, while Ozempic is approved for type 2 diabetes. Ozempic is also frequently prescribed off-label for weight management, which is a different regulatory route to a similar outcome.
- Does insurance cover Wegovy in Canada?
- No provincial public drug plan currently covers a GLP-1 medication for weight loss on its own. Roughly 31% of employer private plans include some coverage for weight-management GLP-1s, so it depends entirely on your specific benefits plan.
- Will a generic version of Wegovy affect pricing here?
- Health Canada approved Sevmia, the first generic referencing Wegovy, in June 2026, and Novo Nordisk has also launched its own authorized generic, Poviztra. Pricing for these alternatives is still settling, but the general trend across GLP-1 generics has been downward as more manufacturers enter the market.